A multi-center study of HRC-101 for the treatment of the patients with moderate refractory ulcerative colitis - A clinical study of HRC-101 for the treatment of ulcerative colitis

开始日期2013-04-18

申办/合作机构

Toray Industries, Inc.

100 项与 HML-109 相关的临床结果

登录后查看更多信息

100 项与 HML-109 相关的转化医学

登录后查看更多信息

100 项与 HML-109 相关的专利（医药）

登录后查看更多信息

项与 HML-109 相关的文献（医药）

2009-11-01·Intensive Care Medicine1区 · 医学

Effect of oxygen affinity on systemic perfusion and brain tissue oxygen tension after extreme hemodilution with hemoglobin–starch conjugates in rats

1区 · 医学

Article

作者: Andrew J. Baker ; C. David Mazer ; Elaine Liu ; Gregory M. T. Hare

PURPOSETo determine the oxygen affinity for optimal tissue oxygen delivery with a hemoglobin-hydroxyethyl starch conjugate (HRC 101).METHODSAnesthetized rats were hemodiluted (180 ml kg(-1)) with low (P(50) approximately 70 mmHg) or high affinity (P(50) approximately 14 mmHg) HRC 101 at hemoglobin (Hb) concentrations near 100 or 70 g l(-1) (n = 6-8). Hippocampal tissue oxygen tension (P(Br)O(2)), blood flow, arterial blood gases, Hb, hematocrit (Hct) and lactate were measured. Data (mean +/- SD) were analyzed by two-way ANOVA.RESULTSHemodilution reduced the hematocrit to 1 +/- 1% in all groups. P(Br)O(2) was best maintained after hemodilution with low affinity HRC 101 at Hb 100 and 70 g l(-1) (25.2 +/- 7.6 and 16.6 +/- 8.3 torr, respectively). P(Br)O(2) decreased (9.5 +/- 9.3 torr, P < 0.05) and serum lactate levels increased (5.0 +/- 1.7 mmol l(-1), P < 0.05) following hemodilution with the high affinity HRC 101 (Hb 100 g l(-1)).CONCLUSIONSHRC 101 with a lower oxygen affinity favored tissue perfusion and maintained P(Br)O(2) after near complete blood volume exchange in rats.

2007-08-01·Anesthesiology1区 · 医学

The Novel Hemoglobin-based Oxygen Carrier HRC 101 Improves Survival in Murine Sickle Cell Disease

1区 · 医学

Article

作者: Crawford, Mark W. ; Carmichael, F J. Lou ; Shichor, Tal ; Adamson, Gord ; Kim, Peter C. W. ; Bell, David ; Engelhardt, Thomas

BackgroundErythrocyte transfusion decreases morbidity in sickle cell disease, but is not without risk. Use of a hemoglobin-based oxygen carrier could offer the benefits of erythrocyte transfusion while reducing related complications. The authors tested the hypothesis that the novel hemoglobin-based oxygen carrier, HRC 101, would improve survival during exposure to acute hypoxia in a murine model of sickle cell disease, the transgenic mouse expressing hemoglobin SAD (alpha2beta2).MethodsWild-type (n = 30) and transgenic SAD (n = 36) mice received 0.02 ml/g HRC 101 (hemoglobin concentration, 10 g/dl) or an equal volume of 5% albumin. Thirty percent or 6% oxygen was administered to spontaneously breathing mice during halothane anesthesia (inspired concentration, 0.5%). The time to cessation of cardiac electrical activity was recorded. Survival was compared using Kaplan-Meier analysis.ResultsControl mice survived the 60-min study period, whether breathing 30% or 6% oxygen. In contrast, all SAD mice given albumin and 6% oxygen died, with a median survival time of 9.0 min (interquartile range, 6.9-11.6 min; P < 0.0001). HRC 101 significantly increased survival in SAD mice breathing 6% oxygen. Of 12 SAD mice given HRC 101 and 6% oxygen, 4 survived the entire study period and 8 died, with a median survival time of 48 min (19-60 min; P < 0.0001 vs. albumin).ConclusionHRC 101 significantly decreased sickle-related mortality during exposure to acute hypoxic stress in transgenic mice expressing hemoglobin SAD. HRC 101 warrants further evaluation as a therapeutic modality in sickle cell disease.

100 项与 HML-109 相关的药物交易

登录后查看更多信息